Literature DB >> 15910304

Cytomegalovirus enhance expression of growth factors during the development of chronic allograft nephropathy in rats.

Kaija Inkinen1, Anu Soots, Leena Krogerus, Raisa Loginov, Cathrien Bruggeman, Irmeli Lautenschlager.   

Abstract

Cytomegalovirus (CMV) accelerates chronic rejection (CRX) in a model of rat kidney allograft. In this model, the expressions of transforming growth factor beta 1 (TGF-beta), platelet-derived growth factor (PDGF)-AA, PDGF-BB and connective tissue growth factor (CTGF) were investigated with and without CMV. Transplantations were performed under immunosuppression. One group of animals was infected with CMV and the other was left uninfected. The grafts were harvested on days 3-60 after transplantation. Growth factor proteins were demonstrated by immunohistochemistry, and mRNAs by in situ hybridization. A significantly more intense and earlier endothelial TGF-beta (2.4 +/- 0.8 vs. 1.0 +/- 0.0; P < 0.05) and PDGF-AA (1.8 +/- 0.4 vs. 1.0 +/- 0.0; P < 0.05) expressions, confirmed by mRNA hybridization, occurred in the CMV group compared with the noninfected group. PDGF-BB appeared in a few inflammatory cells only. In addition CTGF appeared earlier and has more intense in the CMV group (2.5 +/- 0.6 vs. 1.2 +/- 0.5) and the number of CTGF mRNA-positive fibroblasts (57 +/- 9 vs. 3 +/- 4; P < 0.05) was significantly higher. Thus, CMV enhanced expression of TGF-beta1, PDGF-AA and CTGF during the development of CRX.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15910304     DOI: 10.1111/j.1432-2277.2005.00113.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  5 in total

Review 1.  Molecular pathways involved in loss of graft function in kidney transplant recipients.

Authors:  Valeria R Mas; Kellie J Archer; Mariano Scian; Daniel G Maluf
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

Review 2.  Systemic sclerosis: a prototypic multisystem fibrotic disorder.

Authors:  John Varga; David Abraham
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 3.  Acceleration of allograft failure by cytomegalovirus.

Authors:  Daniel N Streblow; Susan L Orloff; Jay A Nelson
Journal:  Curr Opin Immunol       Date:  2007-08-22       Impact factor: 7.486

Review 4.  Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing.

Authors:  D N Streblow; J Dumortier; A V Moses; S L Orloff; J A Nelson
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

5.  Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.

Authors:  Tomas Reischig; Martin Kacer; Petra Hruba; Hana Hermanova; Ondrej Hes; Daniel Lysak; Stanislav Kormunda; Mirko Bouda
Journal:  BMC Infect Dis       Date:  2018-11-15       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.